SEEL
$0.73
Seelos Therapeutics
($.01)
(.85%)
SEEL
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.07)
Revenue:  $0.00 Mil
Thursday
Nov 12
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when SEEL reports earnings?
Beat
Meet
Miss

Where is SEEL's stock price going from here?
Up
Flat
Down
Stock chart of SEEL
Analysts
Summary of analysts' recommendations for SEEL
Score
Grade
Pivots
Resistance
$0.86
$0.83
$0.78

$0.75

Support
$0.71
$0.68
$0.63
Tweet
Growth
Description
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.